Lw-213 Synergizes with Rituximab to Inhibit Diffuse Large B-Cell Lymphomas By Upregulating CD20

被引：0
|
作者：
Li, Yuchen [1 ]
Li, Hui [2 ]
Hui, Hui [1 ]
Xu, Jingyan [3 ]
机构：
[1] China Pharmaceut Univ, Nanjing, Peoples R China
[2] China Pharmaceut Univ, State Key Lab Nat Med, Jiangsu Key Lab Carcinogenesis & Intervent, Nanjing, Peoples R China
[3] Nanjing Drum Tower Hosp, Hematol Dept, Nanjing, Peoples R China
来源：
BLOOD | 2021年 / 138卷
关键词：
CD20 DLBCL Rituximab SOX2 Histone Deacetylation;
D O I：
10.1182/blood-2021-149515
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4366
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Novel HDAC inhibitor Chidamide synergizes with Rituximab to inhibit diffuse large B-cell lymphoma tumour growth by upregulating CD20
    Xu-Wen Guan
    Hua-Qing Wang
    Wei-Wei Ban
    Zhi Chang
    Hai-Zhu Chen
    Li Jia
    Feng-Ting Liu
    Cell Death & Disease, 11
  • [2] Novel HDAC inhibitor Chidamide synergizes with Rituximab to inhibit diffuse large B-cell lymphoma tumour growth by upregulating CD20
    Guan, Xu-Wen
    Wang, Hua-Qing
    Ban, Wei-Wei
    Chang, Zhi
    Chen, Hai-Zhu
    Jia, Li
    Liu, Feng-Ting
    CELL DEATH & DISEASE, 2020, 11 (01)
  • [3] Modulation of CD20 expression in B-cell lymphomas treated with rituximab.
    Seliem, RM
    Freeman, JK
    Hasserjian, RP
    BLOOD, 2002, 100 (11) : 311B - 311B
  • [4] Analysis of CD20 alone could be misleading in lineage determination of B-cell lymphomas: a case of CD20 negative diffuse large B-cell lymphoma in abdominal effusion
    Hoeller, S.
    Tzankov, A.
    Feichter, G.
    Obermann, E.
    Dirnhofer, S.
    CYTOPATHOLOGY, 2009, 20 (04) : 273 - 274
  • [5] THE DIAGNOSTIC CHALLENGE OF RITUXIMAB-INDUCED CD20 NEGATIVE B-CELL LYMPHOMAS
    Risser, J.
    Breen, C.
    Feder, S.
    O'Leary, E.
    JOURNAL OF CUTANEOUS PATHOLOGY, 2011, 38 (01) : 159 - 159
  • [6] Rituximab for the treatment of diffuse large B-cell lymphomas
    Held, Gerhard
    Poschel, Viola
    Pfreundschuh, Michael
    EXPERT REVIEW OF ANTICANCER THERAPY, 2006, 6 (08) : 1175 - 1186
  • [7] Rituximab in the treatment of diffuse large B-Cell lymphomas
    Coiffier, B
    SEMINARS IN ONCOLOGY, 2002, 29 (01) : 30 - 35
  • [8] CD20 mutations involving the rituximab epitope are rare in diffuse large B-cell lymphomas and are not a significant cause of R-CHOP failure
    Johnson, Nathalie A.
    Leach, Stephen
    Woolcock, Bruce
    deLeeuw, Ronald J.
    Bashashati, Ali
    Sehn, Laurie H.
    Connors, Joseph M.
    Chhanabhai, Mukesh
    Brooks-Wilson, Angela
    Gascoyne, Randy D.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 (03): : 423 - 427
  • [9] Establishment of a novel CD20 negative mature B-cell line, WILL2, from a CD20 positive diffuse large B-cell lymphoma patient treated with rituximab
    Takashi Sonoki
    Yaqiong Li
    Setsuko Miyanishi
    Hirokazu Nakamine
    Nobuyoshi Hanaoka
    Hiroshi Matsuoka
    Ichiro Mori
    Hideki Nakakuma
    International Journal of Hematology, 2009, 89 : 400 - 402
  • [10] Establishment of a novel CD20 negative mature B-cell line, WILL2, from a CD20 positive diffuse large B-cell lymphoma patient treated with rituximab
    Sonoki, Takashi
    Li, Yaqiong
    Miyanishi, Setsuko
    Nakamine, Hirokazu
    Hanaoka, Nobuyoshi
    Matsuoka, Hiroshi
    Mori, Ichiro
    Nakakuma, Hideki
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2009, 89 (03) : 400 - 402
12345